Portable Low-Volume Therapy for Severe Blood Loss
Abstract
The primary goal of the research described in the initial Statement of Work is to advance the development of BHB/M so that it is ready for deployment as a portable fast-acting therapy for blood loss. To facilitate deployment, studies will optimize the formulation by increasing our understanding of its mechanism of action in animal models under conditions of 60% blood loss. The low concentration end of the full-factorial design described in Specific Aim 1 was explored in rats. Survival curves were compared after 24 hours using a Wilcoxon test. There was a significant difference (p less than 0.05) in survival: treatment no. 1 (0.4 M D-BHB, 4/3 mM melatonin, 10% DMSO) showed 33% survival; treatment no 2 (2 M D-BHB, 4.3 mM melatonin, 10% DMSO), 71% survival. From our data and that of Klein et al, it appears that the animal requires a high concentration of D-BHB in order to overcome the negative effects of hemorrhagic shock.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2012
- Accession Number
- ADA615953
Entities
People
- Cecilia E. Perez De Lara Rodriguez
- Lester R Drewes
- Matthew T Andrews
Organizations
- University of Minnesota Duluth